Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Payables: 2021-2025

Historic Payables for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $5,611.

  • ProQR Therapeutics N.V's Payables rose 13.29% to $5,611 in Q3 2025 from the same period last year, while for Sep 2025 it was $37,853, marking a year-over-year decrease of 97.74%. This contributed to the annual value of $21,994 for FY2024, which is 98.68% down from last year.
  • ProQR Therapeutics N.V's Payables amounted to $5,611 in Q3 2025, which was up 4.87% from $5,351 recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics N.V's Payables ranged from a high of $43.1 million in Q1 2022 and a low of $4,742 during Q1 2024.
  • Its 3-year average for Payables is $1.2 million, with a median of $5,611 in 2025.
  • In the last 5 years, ProQR Therapeutics N.V's Payables soared by 216,181.09% in 2022 and then crashed by 99.89% in 2024.
  • Over the past 5 years, ProQR Therapeutics N.V's Payables (Quarterly) stood at $5.7 million in 2021, then declined by 16.19% to $4.8 million in 2022, then tumbled by 65.05% to $1.7 million in 2023, then tumbled by 98.68% to $21,994 in 2024, then increased by 13.29% to $5,611 in 2025.
  • Its Payables stands at $5,611 for Q3 2025, versus $5,351 for Q2 2025 and $4,897 for Q1 2025.